Patient Group Direction for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)

Document first published:
Page updated:
Publication type:

This Patient Group Direction (PGD) is for the administration of COVID-19 mRNA vaccine BNT162b2 30micrograms in 0.3ml to individuals in accordance with the national COVID-19 vaccination programme.

Published 11 December 2020 and updated 5 January 2021, 23 March 2021, 6 August 2021 and 20 September and 19 November 2021.


Updated 19 November 2021.